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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S262was then reduced, alkylated and trypsin digested in solution. Digests were
resolved by liquid chromatography-mass spectrometry (LC-MS) using
a linear ion-trap Orbitrap mass spectrometer. Progenesis LC-MS software
(Nonlinear Dynamic) was used for label-free quantiﬁcation with data
searched for protein identiﬁcations using Mascot in the Ensembl database
for horse. Bioinformatics were undertaken for up-regulated and down-
regulated proteins with the enrichment analysis tool of the Con-
sensusPathDB program along with the protein network analysis ‘Search
Tool for Retrieval of Interacting Genes/Proteins’ (STRING) tool.
A cartilage secretome QconCAT was designed and expressed through
recombinant genes in E.coli, cultured in media containing stable isotope
labelled amino acids. The media and QconCATwere reduced, alkylated and
trypsin digested in solution. Quantiﬁcation of cartilage oligomeric matrix
protein and ﬁbromodulin was achieved by comparing the peak area ratios
of heavy (QconCAT) and light (analyte) peptide transitions using a Waters
Xevo-triple quadropole-MS.
Results: 1D SDS PAGE and LC-MS elucidated both qualitative differences
and treatment induced changes in relative protein abundance in the
secretome protein proﬁles of explants models of early OA. We identiﬁed
a total of 295 proteins; 100 differentially expressed in the early OA model.
19% of down-regulated proteins were attributed to ‘ECM’ and 13.8% of up-
regulated proteins to ‘glycolysis’ using gene ontology. Pathway enrichment
analyses conﬁrmed the up-regulation of glycolytic and glucose-related
proteins. Novel proteins clathrin and LIM and SH3 domain protein-1 were
identiﬁed for the ﬁrst time in cartilage proteomics. Cartilage oligomeric
matrix protein increased in the early OA secretome from 3642 to 6505
pmol/g dry weight, but no signiﬁcant change in ﬁbromodulin was
identiﬁed.
Conclusions: A highly sensitive proteomic comparison together with
insightful data mining enabled us to identify proteins and pathways
involved in early OA which could aid the development of early OA diag-
nostic markers and therapeutics.
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Purpose: Obesity, an important risk factor for osteoarthritis (OA), induces
inﬂammatory changes in adipose tissue. The infrapatellar fat pad (IPFP)
present in the knee joint is considered as an active osteoarthritis joint
tissue contributing to local inﬂammatory and destructive processes.
However, soluble mediators released by IPFP involved in these processes
are largely unknown. Eicosanoids are essential mediators of the inﬂam-
matory response and contribute to the initiation and the resolution of
inﬂammation. In this study we aimed to detect differences between
healthy and OA derived IPFP based on their secretion of lipid mediators
involved in the eicosanoid pathway.
Methods: IPFP explants of 13 OA donors (joint replacement surgery) and
11 donors with macroscopically healthy knee joints (post-mortem) were
cultured for 24 hours (50 mg IPFP explant/ml) and the supernatant was
collected. Fat conditioned medium (FCM) samples were measured by an
LC-MS/MS method for lipid mediators of inﬂammation (e.g. oxylipids,
eicosanoids). Data were subjected to univariate and multivariate statistical
analyses.
Results: On an individual basis, lipid mediators involved in the eicosanoid
pathway were not signiﬁcantly different between OA and healthy FCM.
However, when assessed with multivariate statistical analysis (PLS-DA) 14
out of 29 quantiﬁed eicosanoids were found to be important to distinguish
OA from healthy FCM. Lipoxin A4, considered as an important anti-
inﬂammatory oxylipid, was the most discriminative eicosanoid in the
model with lower levels in OA than in healthy FCM. Prostaglandins (PG)
derived from eicosapentaenoic acid (EPA) are generally regarded as anti-inﬂammatory and lower levels of PGD3 were found in OA FCM. In contrary,
no changes in level of EPA were observed. Remarkably, the levels of
docosahexaenoic acid (DHA) and its derived precursor for resolvin D1,
generally regarded as anti-inﬂammatory, were higher in OA FCM. The level
of the fatty acid arachidonic acid (AA), generally regarded as a precursor
for pro-inﬂammatory PG, was higher in OA than in healthy FCM. This was
supported by a higher level of PGF2alfa and PGD2 in OA
FCM. Conversely, AA-derived PGB2 and PGF2beta levels were lower.
Furthermore, OA patients showed increased concentrations of throm-
boxane A2. Linoleic acid-derived eicosanoids 9-HODE and 13-HODE, major
components of ox-LDL and regarded as markers for lipid peroxidation,
were lower in OA. Overall, the differences observed between healthy and
OA FCM could not be attributed to basal metabolism changes, because
downstream products of a certain pathway were differentially affected
(e.g. PG derived from AA).
Conclusions:OA patients can be distinguished from healthy persons based
on their IPFP secretion of lipid mediators involved in the eicosanoid
pathway. However, these differences are small, since none of the distinc-
tive eicosanoids were signiﬁcantly altered on an individual basis. Based on
biological pathway analyses the eicosanoid proﬁle associated with OA is
likely to be speciﬁcally regulated by the disease process rather than due to
basal metabolism changes or generic enzyme alterations. In general, pro-
inﬂammatory eicosanoids appear to be higher and anti-inﬂammatory
appear to be lower in OA than in healthy FCM which strengthens our
hypothesis, but there are exceptions. These data provide new insight in
mechanisms important for the pathogenesis of OA.
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THE PROTEOME OF YOUNG AND HEALTHY HUMAN HAMSTRING
O. Hakimi, N. Ternette, R. Murphy, B. Kessler, A. Carr. Oxford Univ., Oxford,
United Kingdom
Purpose: Despite ongoing research into tendon disease, the exact content
of the extracellular matrix of tendon remains partially described. For
example, only few markers are used for tendon, and the majority of these
are non-speciﬁc. This limits the ability to distinguish tendon cells from
other ﬁbroblasts of the musculoskeletal system and the understanding of
pathological tendon. To date, most studies of tendon phenotype focused on
tendon-derived cells in vitro or animal models such as an acutely inﬂamed
rat Achilles. Thus, the motivation exists to characterize healthy, young,
human tendon. A better inventory of tendon proteins can be used to
identify markers and serve as a comparison for diseased or aging tendon
tissue. Here, we analyzed the protein composition of repeated biopsies
from a single human tendon removed from a young patient undergoing
ACL repair by quantitative tandem mass spectrometry. This study was
designed to test the repeatability of the homogenization, sampling and
analysis, as well as produce a preliminary tendon inventory of healthy,
young human Hamstring.
Methods: Tissue acquisition- Hamstring tissue (the end of an auto-graft)
was collected from a 23 years old male patient undergoing ACL repair.
Approval was obtained from the local Research Ethics Committee. Sample
processing- 4 rice-grain sized samples were cut from the tissue and pro-
cessed individually by suspension in guanidine hydrochloride and
homogenization in a gentleMacs dissociator (Miltenyi Biotec). Proteins
were precipitated using chloroform/methanol and digested with trypsin.
Peptides were puriﬁed using a C18 Sep-pak column (Waters). Sample
analysis- Equal amounts of peptide material were analyzed by UPLC
(nanoAquity, Waters) online coupled to an LTQ Orbitrap Velos (Thermo
Scientiﬁc). Peptides were eluted by applying a 180 min linear gradient
from 3% buffer A (0.1% formic acid in water) to 40% buffer B (0.1% formic
acid in acetonitrile) on a C18 column (waters). Higher-energy C-trap
dissociation (HCD) was induced on the ten most abundant ions per full MS
scan. Data analysis- All samples were analyzed in triplicates. Identiﬁcation
and quantitation was performed using MASCOT (v2.3.01) derived emPAI
values.
Results: Overall, 244 proteins were identiﬁed. The variation of the tech-
nical repeats (within each biopsy) was small, as demonstrated by the Venn
diagrams (Figure 1), conﬁrming the accuracy of the instrumentations as
well as the homogeneity of the samples. Furthermore, the relatively small
variation between the biopsies of the sample tendon (Figure 1D) points to
